Full-Time

Medical Director

Clinical Development

Updated on 9/3/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$266k - $340k/yr

+ Annual bonus + Long-term incentive award + Equity

Boston, MA, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday; additional on-site days may be required.

MBA, PhD, MD

Category
Biology & Biotech
Required Skills
Data Analysis

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • An advanced clinical degree (MD or DO) or MD/PhD is required.
  • A minimum of 5 years of combined clinical and pharmaceutical or biotechnology industry experience is required.
  • Direct experience treating or managing lupus (SLE and/or CLE) and/or systemic sclerosis patients or clinical programs is strongly preferred.
  • Deep scientific expertise in autoimmune disease, particularly rheumatology, lupus (SLE and/or CLE), or systemic sclerosis, is preferred.
  • Direct experience with Phase 1–3 clinical studies, including authoring clinical trial protocols, clinical development plans, and regulatory submission documents, is required.
  • Deep clinical and scientific expertise in immunology and inflammation, including disease mechanisms, clinical trial landscapes, standard-of-care evolution, regulatory developments, and emerging therapeutic approaches, is required.
  • The ability to identify, characterize, and mitigate clinical, operational, and regulatory risks across multisite, multinational clinical programs is required.
  • The ability to lead and influence cross-functional teams in a matrixed, fast-paced biotechnology or pharmaceutical environment without direct line authority is required.
  • The ability to build alignment across diverse internal and external stakeholders, including senior leadership, clinical operations, regulatory, and commercial partners, is required.
  • A track record of driving program-level decisions with clarity and accountability while balancing scientific rigor with business urgency in resource-constrained settings is required.
  • Exceptional scientific communication skills are required to articulate complex medical and clinical data to senior leadership, health authorities, clinical investigators, and external partners.
  • Demonstrated scientific writing proficiency is required, including the ability to evaluate and present complex data sets in regulatory documents, clinical study reports, and scientific publications.
  • The ability to facilitate high-stakes discussions, including advisory boards, cross-functional program reviews, and health authority interactions, with confidence and precision is required.
Responsibilities
  • Lead and provide medical oversight for assigned clinical trials, including protocol development, study conduct, medical monitoring, data review and interpretation, and clinical study reporting.
  • Contribute to clinical development strategy and program plans by integrating scientific rationale, regulatory requirements, safety considerations, operational feasibility, and business objectives.
  • Provide medical leadership on trial design, including endpoint selection, eligibility criteria, dose rationale, biomarker strategy, risk-based monitoring, and interim analysis frameworks.
  • Monitor real-time data collection throughout study conduct to ensure robust study conduct and protocol adherence.
  • Support pharmacovigilance activities during trial conduct by monitoring patient safety and benefit-risk through review of adverse events, serious adverse events, laboratory data, safety narratives, and aggregate safety information, and contribute to related safety governance activities in coordination with the Global Pharmacovigilance Medical Director.
  • Serve as a key medical resource for investigative sites, external advisors, and clinical investigators by ensuring patients meet appropriate eligibility criteria, responding to clinical and safety inquiries, and supporting external interactions, advisory boards, and scientific communications as appropriate.
  • Lead and conduct peer-to-peer scientific exchange with key medical experts, investigators, and healthcare professionals by sharing clinical and emerging data, discussing unmet medical needs, and gathering external insights that inform overall development strategy.
  • Review, author, and contribute to key clinical and regulatory documents, including protocols, protocol amendments, investigator brochures, informed consent forms, clinical study reports, briefing materials, and health authority responses.
  • Support regulatory interactions and submissions by providing medical and scientific input for agency meetings, annual reports, and clinical sections of regulatory filings.
  • Serve as the clinical development lead for an asset if required.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Board certification or clinical training in rheumatology, nephrology, immunology, or a related specialty.
  • An additional advanced degree such as a PhD, Master of Public Health, or Master of Business Administration.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...